Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorecivivint - Biosplice Therapeutics

Drug Profile

Lorecivivint - Biosplice Therapeutics

Alternative Names: Adavivint - Biosplice Therapeutics; SM-04690

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samumed
  • Developer Biosplice Therapeutics
  • Class Amides; Anti-inflammatories; Antirheumatics; Fluorinated hydrocarbons; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Clk dual-specificity kinase inhibitors; DYRK kinase inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Preclinical Intervertebral disc degeneration

Most Recent Events

  • 18 Apr 2024 Biosplice Therapeutics plans to meet US FDA and other regulatory agencies for approval of lorecivivint
  • 20 Feb 2024 Biosplice Therapeutics completes the phase-III STRIDES trial in Osteoarthritis in USA (Intra-articular) (NCT05603754)
  • 13 Nov 2023 Updated efficacy and adverse events data from a phase III trial in Osteoarthritis released by Biosplice Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top